Long term safety and efficacy of autologous stem cell transplantation for the treatment of type 2 diabetes mellitus

      Background: Autologous stem cell therapies are emerging set of therapies which help in regeneration and differentiation of β-cells with promising outcomes and very low incidence of adverse effects. The aim of the study is to assess the safety and efficacy of selective intra-arterial Autologous stem cells (ASCs) infusion in metabolic control with reduction in HbA1c and improvement in β-cell function (c-peptide), contributing to the reduction of OHA and insulin requirements.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect